Results 81 to 90 of about 729,378 (199)
Stroke, 2006 In this issue of Stroke , the Atherosclerosis Risk in Communities (ARIC) study provides evidence that lipoprotein(a) [Lp(a)] is a significant predictor of stroke.1 This is an important finding, because ARIC is both large and prospective. Over 14 000 patients were enrolled in 1987 to 1989, and during 13.5 years of follow-up, they experienced 496 ...
openaire +1 more source
Lipids in Health and Disease, 2019 Background Atherosclerosis is an inflammatory process involving activation of monocytes recruited by various chemoattractant factors, among which lipoprotein(a) and its specific apolipoprotein apo(a). Lp(a) contains a specific apolipoprotein apo(a) which
Nadia Sabbah +4 more
doaj +1 more source
Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial. [PDF]
, 2017 Extended-release niacin (ERN) is the most effective agent for increasing high-density lipoprotein-cholesterol (HDL-C). Having previously identified anti-HDL antibodies, we investigated whether ERN affected the antioxidant capacity of HDL and whether ERN ...
Alves, JD +6 more
core +1 more source
Journal of Lipid ResearchLipoprotein (a) [Lp(a)] is viewed as a cholesterol-rich, LDL-like particle, yet potential heterogeneity in its lipid composition is not well understood.
Lizhu Lin +3 more
doaj +1 more source
Lipoprotein(a) at a “Tipping Point”: case to move to universal screening
American Journal of Preventive CardiologyElevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) levels are >90 % genetically determined.
Harpreet S. Bhatia
doaj +1 more source
Indian Heart JournalLp(a) is a genetically determined, heritable, independent and causal risk factor for ASCVD. About 1 in 5 people worldwide have elevated Lp(a) (>50 mg/dL or >125 nmol/L) whereas in Indians it is 25 %. Epidemiological, genome-wide association and mendelian randomization studies have demonstrated an association between elevated Lp(a) levels and increased ...
openaire +3 more sources
Reclassification of Low or Intermediate Cardiovascular Risk by Determining Lipoprotein(a) Levels
BiomedicinesBackground: Lipoprotein(a) [Lp(a)] is a modifier of cardiovascular risk, and it should be determined at least once in a lifetime. Methods: Subjects with low or moderate cardiovascular risk, estimated by SCORE2, were invited to have a determination of Lp ...
Alberto Cordero +5 more
doaj +1 more source
SERUM LIPOPROTEIN (a) LEVELS IN HEMODIALYSIS PATIENTS
Turkish Journal of Nephrology, 2019 İn our hemodialysis center, serum Lipoprotein (a) {Lp(a)j, Apoprotein Ai (ApoAi) and Apoprotein B (Apo B) levels were examined in 50 patients and 50 healthy controls.
Mahmut YAVUZ +4 more
doaj